The creation of the Rapamycin Fly Cell Atlas reveals that entirely different cell types across the body drift into a single, shared degenerative state during aging. Rapamycin selectively dismantles this “Convergent Aging Trajectory,” primarily benefiting the reproductive, digestive, and neuromuscular systems while exhibiting a profound, built-in bias toward female biology.
For decades, science has viewed aging as a highly fragmented breakdown—a chaotic process where the heart ages one way, the gut another, and the brain yet another. However, a groundbreaking whole-organism single-nucleus transcriptomic study has turned this paradigm on its head, exposing a hidden cosmic convergence in how cells decay. By sequencing over 505,000 cell nuclei across the lifespan of Drosophila melanogaster, researchers built the Rapamycin Fly Cell Atlas (Rapa-FCA). The headline discovery is the Convergent Aging Trajectory (CAT): a universal genetic vortex where cells from wildly different lineages—such as ovaries, intestines, and nerves—slowly lose their unique identities and sink into an identical profile of metabolic panic.
As organisms grow old, these diverse cells uniformly turn up genes regulating glycolysis and fat synthesis, driven by chronic activation of the nutrient-sensing master regulator, mTORC1. The accumulation of these “CAT-high” cells acts as an internal biological clock, predicting tissue failure and imminent death.
Enter rapamycin, the gold-standard longevity drug. Instead of acting as a generic cellular blanket, rapamycin hunts down these CAT-high cells. The drug specifically engages with Fkbp12—an intracellular cellular cofactor that is highly enriched in these converging, aged cell populations—effectively hitting the brakes on their metabolic decline.
Crucially, this blueprint unmasks the molecular basis of a well-known longevity mystery: why rapamycin favors females. Female flies accumulate vastly more CAT-high cells across their organs than males do. Because females harbor a much higher burden of this specific, rapamycin-sensitive cellular substrate, they possess more targets for the drug to rescue. By suppressing this shared cellular state, rapamycin acts as a master clinical rejuvenator across multiple organ systems simultaneously, showing that longevity interventions can target a singular cellular state rather than chasing a hundred separate diseases.
Context/Source
- Open Access (bioRxiv Preprint): Rapamycin Mitigates a Sex-biased Convergent Aging Trajectory
- Lead Institution: Baylor College of Medicine
- Country: United States (with contributing authors from Harvard Medical School, USA, and Academia Sinica, Taiwan)
- Journal Name: bioRxiv
- Impact Evaluation: The impact score of this journal is 0 (unrated preprint repository).